| 黄丹琪,杨 敏,王慧琳,等.1990—2021年中国与全球非吸烟女性人群恶性肿瘤的疾病负担分析[J].中国肿瘤,2025,34(8):636-644. |
| 1990—2021年中国与全球非吸烟女性人群恶性肿瘤的疾病负担分析 |
| Disease Burden of Malignant Tumors in Chinese and Global Non-Smoking Female Population from 1990 to 2021 |
| 投稿时间：2025-01-15 |
| DOI：10.11735/j.issn.1004-0242.2025.08.A005 |
|
 |
| 中文关键词: 恶性肿瘤 非吸烟 女性 疾病负担 中国 全球 |
| 英文关键词:malignant tumors non-smoking female burden of disease China global |
| 基金项目:中国癌症基金会北京希望马拉松专项基金（LC2021A05） |
|
| 摘要点击次数: 267 |
| 全文下载次数: 133 |
| 中文摘要: |
| 摘 要：［目的］ 分析1990—2021年中国与全球非吸烟女性人群恶性肿瘤的疾病负担及其变化趋势。［方法］ 从2021年全球疾病负担研究项目（Global Burden of Disease 2021，GBD 2021）提取1990—2021年中国与全球非吸烟女性恶性肿瘤死亡和伤残调整寿命年（disability-adjusted life year，DALY）数据。采用Joinpoint回归模型分析中国与全球各个疾病负担指标的平均年度变化百分比（average annual percentage change，AAPC）。 ［结果］ 1990—2021年，中国非吸烟女性人群恶性肿瘤死亡病例数由13.71万例增加至26.81万例，与全球相比，上升更明显（中国：AAPC=2.19%，95%CI：2.06%~2.33%；全球：AAPC=1.92%，95%CI：1.80%~2.04%，P=0.003）；标化死亡率由32.42/10万减少至24.58/10万，较全球下降得更明显（中国：AAPC=-0.88%，95%CI：-1.00%~-0.76%；全球：AAPC=-0.59%，95%CI：-0.68%~-0.51%，P<0.001）。中国恶性肿瘤DALY由412.96万人年增加至691.20万人年，与全球上升趋势相似（中国：AAPC=1.68%，95%CI：1.56%~1.81%；全球：AAPC=1.63%，95%CI：1.52%~1.75%，P=0.536）；标化DALY率由889.58/10万减少至642.65/10万，较全球下降得更明显（中国：AAPC=-1.04%，95%CI：-1.15%~-0.92%；全球：AAPC=-0.69%，95%CI：-0.78%~-0.61%，P<0.001）。2021年中国标化死亡率排名前5位的恶性肿瘤分别为肺癌、结直肠癌、宫颈癌、乳腺癌和肝癌；全球标化死亡率排名前5位的恶性肿瘤分别为宫颈癌、结直肠癌、乳腺癌、肺癌和胰腺癌。中国乳腺癌、肝癌、胰腺癌和子宫体癌的标化死亡率、标化DALY均呈整体上升趋势（P均<0.05）。 ［结论］ 1990—2021年中国与全球非吸烟女性恶性肿瘤的死亡病例数和DALY均呈整体上升趋势，标化死亡率和标化DALY率均呈整体下降趋势。在未来，需要采取更有针对性的恶性肿瘤预防措施，以降低非吸烟女性人群恶性肿瘤的疾病负担。 |
| 英文摘要: |
| Abstract： ［Purpose］ To analyze the disease burden of malignant tumors and its changing trends in Chinese and global non-smoking female population from 1990 to 2021. ［Methods］ Data of mortality and disability-adjusted life year (DALY) due to malignant tumors for Chinese and global non-smoking female malignant tumors from 1990 to 2021 were extracted from the Global Burden of Disease Study 2021 (GBD 2021)， and the average annual percentage change (AAPC) were calculated using Joinpoint regression model. ［Results］ From 1990 to 2021， the number of deaths for malignant tumors in Chinese non-smoking female population increased from 13.71×104 to 26.81×104， with a higher increased trend compared with the global (China： AAPC=2.19%， 95%CI： 2.06%~2.33%； Global： AAPC=1.92%， 95%CI： 1.80%~2.04%， P=0.003)； the age-standardized mortality rate decreased from 32.42/105 to 24.58/105， with a higher decreased trend compared with the global (China： AAPC=-0.88%， 95%CI： -1.00%~-0.76%； Global： AAPC=-0.59%， 95%CI： -0.68%~-0.51%，P<0.001). From 1990 to 2021， the DALY for malignant tumors in Chinese non-smoking female population increased from 412.96×104 to 691.20×104 person-years， with a similar changing trend compared with the global (China： AAPC=1.68%， 95%CI： 1.56%~1.81%， Global： AAPC=1.63%， 95%CI： 1.52%~1.75%， P=0.536)； the age-standardized DALY rate in Chinese non-smoking female population decreased from 889.58/105 to 642.65/105， with a higher decreased trend compared with the global (China： AAPC=-1.04%， 95%CI： -1.15%~-0.92%； Global： AAPC=-0.69%， 95%CI： -0.78%~-0.61%， P<0.001). The top five malignant tumors of high age-standardized mortality rate in Chinese non-smoking female population in 2021 were tracheal， bronchus and lung cancer， colon and rectum cancer， cervical cancer， breast cancer， and liver cancer. The top five malignant tumors of high age-standardized mortality rate globally in 2021 were cervical cancer， colon and rectum cancer， breast cancer， tracheal， bronchus and lung cancer， and pancreatic cancer. The age-standardized mortality rate and DALY rate of breast cancer， liver cancer， pancreatic cancer and corpus cancer showed overall upward trends (all P<0.05). ［Conclusion］ From 1990 to 2021， the number of deaths and DALY of malignant tumors in Chinese and global non-smoking female population showed overall increased trends， and age-standardized mortality rate and DALY rate showed overall decreased trends. In future， more targeted cancer prevention measures are needed to reduce the disease burden of malignant tumors in non-smoking female population. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |